Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Clinical trial NCT02795182 · COMPLETED
Trial details
- NCT number
- NCT02795182
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-29
- Primary completion
- 2020-12-18
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.